Javascript was detected to be disabled. Javascript is required for some functions on this website.

Publications

Here we offer access to some of our recent publications, including the Discussion Paper series issued by our Institute.

Please visit us again as we will continuously update and extend this website.

Discussion Papers

2015

M. Schlander, K. Stenner, A. Gandjour:

Budgetary Impact and Cost Drivers of Drugs for Ultra-Rare Diseases (URDs) in Europe.

InnoValHC Discussion Paper No. 32 / 2015 (ISBN 978 3 941609 31 0).

M. Schlander, S. Holm, E. Nord, J. Richardson, S. Garattini, P. Kolominsky-Rabas, D. Marshall, U. Persson, M. Postma, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi:

Towards Social Cost Value Analysis: The Need for New Approaches for Evaluating Drugs for Ultra-Rare Diseases (URDs).

InnoValHC Discussion Paper No. 31 / 2015 (ISBN 978 3 941609 30 3).

TOP

2014

M. Schlander, C.C. Adarkwah, A. Gandjour:

Budget Impact of Drugs for Ultra-Rare Non-Oncological Diseases Projected to Remain Moderate in Europe.

InnoValHC Discussion Paper No. 30 / 2014 (ISBN 978 3 941609 29 7).

TOP

2013

M. Schlander, S. Garattini, S. Holm, P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J.  Richardson, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi:

Beyond Incremental Cost per Quality-Adjusted Life Year (QALY) Ratios:  The Need for Alternative Methods to Evaluate Medical Interventions for Ultra-Rare Disorders.

InnoValHC Discussion Paper No. 29 / 2013 (ISBN 978 3 941609 28 0).

A. Gandjour, A. Gafni, M. Schlander:

Determining the Price for Pharmaceuticals in Germany:  Comparing a shortcut for IQWiG’s efficiency frontier method with the price set by the manufacturer for ticagrelor.

InnoValHC Discussion Paper No. 28 / 2013 (ISBN 978 3 941609 27 3).

M. Schlander, S. Garattini, P. Kolominsky-Rabas, E. Nord, U. Persson, M. Postma, J. Richardson, S. Simoens, O. de Solà Morales, K. Tolley, M. Toumi:

Consensus Statement: “Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders (URDs).”

also: InnoValHC Discussion Paper No. 27 / 2013 (ISBN 978 3 941609 26 6).

M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Strupler,  P. Suter:

Schweizer HTA-Konsensus, Umsetzungspapier 6/2012: Wirtschaftlichkeitsbewertung.

Basel, Bern, Solothurn and Wiesbaden, February 04, 2013.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 26 / 2013  (ISBN 978 3 941609 25 9).

M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Strupler, P. Suter:

Schweizer HTA-Konsensus, Umsetzungspapier 5/2012: Nutzenbewertung.

Basel, Bern, Solothurn and Wiesbaden, February 04, 2013.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 25 / 2013  (ISBN 978 3 941609 24 2).

M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Strupler,  P. Suter:

Schweizer HTA-Konsensus, Umsetzungspapier 4/2012: Konkretisierung der WZW-Kriterien.

Basel, Bern, Solothurn and Wiesbaden, February 04, 2013.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 24 / 2013  (ISBN 978 3 941609 23 5).

TOP

2012

M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, A. Faller, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Suter:

Schweizer HTA-Konsensus, Umsetzungspapier 3/2012: Complete (c-) HTAs.

Basel, Bern, Solothurn and Wiesbaden, November 13, 2012.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 23 / 2012  (ISBN 978 3 941609 22 8).

M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, A. Faller, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Suter:

Schweizer HTA-Konsensus, Umsetzungspapier 2/2012: Rapid (r-)HTAs.

Basel, Bern, Solothurn and Wiesbaden, November 13, 2012.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 22 / 2012  (ISBN 978 3 941609 21 1).

M. Schlander, H. Sandmeier, C. Affolter, C. Bosshard, T. Cueni, A. Faller, P. Gyger, A. Hebborn, K. Huber, E. Kraft, P. Suter:

Schweizer HTA-Konsensus, Umsetzungspapier 1/2012: Institutionelles.

Basel, Bern, Solothurn and Wiesbaden, November 13, 2012.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 21 / 2012  (ISBN 978 3 941609 20 4).

M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, E. Kraft, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter:

Schweizer HTA-Konsensus-Projekt: Leitsätze.

Basel, Bern, Solothurn and Wiesbaden, May 14, 2012.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 20 / 2012  (ISBN 978 3 941609 19 8).

M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, E. Kraft, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter:

Swiss HTA Consensus:  Guiding Principles.

Basel, Bern, Solothurn and Wiesbaden, March 13, 2012.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 19 / 2012  (ISBN 978 3 941609 18 1).

TOP

2011

M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter: 

Swiss HTA Consensus Project:  Cornerstones for Further Development in Switzerland.

Basel, Bern, Solothurn and Wiesbaden, October 19, 2011.
also: InnoValHC Discussion Paper No. 18 / 2011  (ISBN 978 3 941609 17 4).

M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter:

Schweizer HTA-Konsensus-Projekt:  Eckpunkte für die Weiterentwicklung in der Schweiz.  (Health Technology Assessment (HTA): Systematische Bewertung medizinischer Interventionen in der sozialen Krankenversicherung.)

Basel, Bern, Solothurn and Wiesbaden, October 19, 2011.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 17 / 2011  (ISBN 978 3 941609 16 7).

M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter: 

Schweizer HTA-Konsensus-Projekt:  Eckpunkte für die Weiterentwicklung in der Schweiz. (Health Technology Assessment (HTA): Systematische Bewertung medizinischer Interventionen in der sozialen Krankenversicherung.) Anhang.

Basel, Bern, Solothurn and Wiesbaden, October 19, 2011.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 16 / 2011  (ISBN 978 3 941609 15 0).

M. Schlander, C. Affolter, H. Sandmeier, U. Brügger, C. Cao, T. Cueni, G. de Pouvourville, A. Faller, P. Gyger, A. Hebborn, D. Herren, S. Kaufmann, R. Leu, P. Suter:

Value and Valuation of Health Technologies: 
Bewertung medizinischer Interventionen in der sozialen Krankenversicherung.  Dokumentation zum Thesenpapier (Eckpunkte des Schweizer HTA-Konsensus).

Basel, Bern, Solothurn and Wiesbaden, October 19, 2011.

(see also www.swisshta.ch)
also: InnoValHC Discussion Paper No. 15 / 2011  (ISBN 978 3 941609 14 3).

TOP

2010

M. Schlander:

DIMDI HTA-Bericht Nr. 108: „Medikamentöse Therapie der ADHS im Erwachsenenalter in Deutschland“ - Validität der Schlussfolgerungen, Methodik und Aussagekraft.

InnoValHC Discussion Paper No. 14 / 2010  (ISBN 978 3 941609 13 6).

M. Schlander:

Sponsorship Bias in Health Economic Evaluations of Child Psychiatric Drug Treatment.

InnoValHC Discussion Paper No. 13 / 2010  (ISBN 978 3 941609 12 9).

M. Schlander:

Rational Treatment Choices in Attention-Deficit/Hyperactivity Disorder:
The Contribution of Health Economics.

InnoValHC Discussion Paper No. 12 / 2010  (ISBN 978 3 941609 11 2).

TOP

2009

M. Schlander, G.-E. Trott, O. Schwarz:

Estimating the cost of attention-deficit/hyperactivity disorder (ADHD) in Germany. 
[Available in German: Wie teuer sind Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörungen für die Gesetzliche Krankenversicherung in Deutschland?]

InnoValHC Discussion Paper No. 11 / 2009  (ISBN 978 3 941609 10 5).

M. Schlander, J. Meyer:

Comparative Evaluation of Medical Technologies.

InnoValHC Discussion Paper No. 10 / 2009   (ISBN 978 3 941609 09 9).

M. Schlander:

Comparative Effectiveness Programs: A Global Perspective, Discussing Germany and the United Kingdom. Briefing Document for The Galen Institute, Washington, DC.

also: InnoValHC Discussion Paper No. 09 / March 2009  (ISBN 978 3 941609 08 2).

M. Schlander, O. Schwarz, A. Rothenberger, V. Roessner:

Tic disorders: prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample.

InnoValHC Discussion Paper No. 08 / January 2009  (ISBN 978 3 941609 07 5).

TOP

2008

M. Schlander:

In Search of Efficiency. 
[Available in German: Der Effizienz auf der Spur]

InnoValHC Discussion Paper No. 07 / July 2008  (ISBN 978 3 941609 06 8).

TOP

2007

M. Schlander:

House of Commons Health Committee Inquiry into aspects of the work of the National Institute for Health and Clinical Excellence.

InnoValHC Discussion Paper No. 06 / May 2007  (ISBN 978 3 941609 05 1).

C. Thielscher, M. Schlander:

How Much Glasnost for German Health Care? 
[Available in German: Wieviel Glasnost braucht das deutsche Gesundheitswesen?].

InnoValHC Discussion Paper No. 05 / January 2007  (ISBN 978 3 941609 04 4).

TOP

2006

M. Schlander:

That Infamous Fourth Hurdle: Ten Things to Consider When Regulating Reimbursement of New Drugs in Germany. 
[Available in German: Rationaler Umgang mit neuen Medikamenten: Zehn Thesen zur geplanten „Vierten Hürde“ für neue Arzneimittel.]

InnoValHC Discussion Paper No. 04 / November 2006 [2nd edition]  (ISBN 978 3 941609 03 7).

M. Schlander:

Long-Acting Medications for the Hyperkinetic Disorders.

InnoValHC Discussion Paper No. 03 / September 2006   (ISBN 978 3 941609 02 0).

M. Schlander:

Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on Prescription Drug Spending for Children and Adolescents: Increasing Relevance of Health Economic Evidence.

InnoValHC Discussion Paper No. 02 / June 2006  (ISBN 978 3 941609 01 3).

TOP

2005

M. Schlander, C. Thielscher, O. Schwarz:

Affordable Health Care Expenditure and Real Economic Growth.

InnoValHC Discussion Paper No. 01 / July 2005   (ISBN 978 3 941609 00 6).

TOP